Abstract
The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 (2019-nCoV) has devastated global healthcare and economies. Despite the stabilization of infectivity rates in some developed nations, several countries are still under the grip of the pathogenic viral mutants that are causing a significant increase in infections and hospitalization. Given this urgency, targeting of key host factors regulating SARS-CoV-2 life cycle is postulated as a novel strategy to counter the virus and its associated pathological outcomes. In this regard, Poly (ADP)-ribose polymerase-1 (PARP-1) is being increasingly recognized as a possible target. PARP-1 is well studied in human diseases such as cancer, central nervous system (CNS) disorders and pathology of RNA viruses. Emerging evidence indicates that regulation of PARP-1 by non-coding RNAs such as microRNAs is integral to cell survival, redox balance, DNA damage response, energy homeostasis, and several other cellular processes. In this short perspective, we summarize the recent findings on the microRNA/PARP-1 axis and its therapeutic potential for COVID-19 pathologies.
Highlights
The rapidly evolving coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents an urgent and unmet clinical need for novel therapeutics [1,2]
We showed that Poly (ADP)-ribose polymerase-1 (PARP-1)-mediated PARylation of nuclear p53 maintains the intracellular ATP pool via transactivation of Proline oxidase (POX) mRNA [46]
Several pieces of evidence exist for the binding of miRNAs to be0 important in cancer, cell metabolism, stress response, DNA damage, and neuronal to 5 -30 -untranslated region (UTR), and the open reading frame (ORF) of mRNAs to induce post-transcriptional differentiation and signaling, in addition to drug abuse [18,52,53,54]
Summary
The rapidly evolving coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents an urgent and unmet clinical need for novel therapeutics [1,2]. Pertaining to the miRNA-mediated regulation of PARP-1 in the context of COVID-19 how relevant is PARP-1’s activity across cell/tissue typesacross in SARS-CoV-2 and pathogenesis.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
